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Abstract 
Kinetic, saturation and competition binding assays were employed to optimize and validate radioligand binding methods for 
characterization f recombinant human a2-adrenoceptor subtypes and for screening of new subtype-selective ligands. Stable transfected 
lines of Shionogi 115 mouse mammary tumour cells (Sl15) and three structurally different antagonist radioligands, [3H]rauwolscine, 
[3H]atipamezole and [3H]RX821002, were used. Specificity of a2-adrenergic binding was defined with 100 /zM (-)-adrenaline. 
Steady-state was reached with all three radioligands within 15-30 min at 25°C, and the binding was rapidly reversible. The receptor 
affinities (a2-C10) were highest in glycylglycine, almost equally high in K+-phosphate, and lowest in Tris buffer for all three 
[3H]-ligands. This was mainly caused by different association rates. [3H]RX821002 was bound with high affinity and similar kinetic 
properties to all three a2-adrenoceptor subtypes in K+-phosphate buffer, and had the highest proportion of specific binding (96-98%). 
[3H]RX821002 and K+-phosphate buffer were subsequently used in competition assays. The rank order of affinity of compounds 
selective for a2-adrenoceptor subtypes was a2-Cl0 > ce2-C4 > ce2-C2 for oxymetazoline, a2-C4 > ot2-C2 > a2-Cl0 for prazosin and 
a2-C2 > az-C4 > o~2-C10 for chlorpromazine. The drug affinities (K  i values) determined in this system were in close agreement with 
earlier results with [3H]rauwolscine in Tris buffer ( r= 0.94). Agonist competition for [3H]RX821002 binding was biphasic in 
K+-phosphate buffer supplemented with 10 mM MgCI 2, indicating functional coupling of receptors to G-proteins. Accordingly 
high-affinity binding of the agonists (-)-noradrenaline and UK14,304 was eliminated by 10 /zM Gpp(NH)p in the assays. Our results 
confirm that [3H]RX821002 is a suitable radioligand for the characterization f all three human a2-adrenoceptor subtypes and for the 
determination f the subtype-selectivity of new a2-adrenoceptor agonists and antagonists. 
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I. Introduction 
Radioligand binding assays are important for drug dis- 
covery and development. The availability of recombinant 
human receptors facilitates their use by providing an ample 
source of well defined receptor material and by helping to 
avoid problems related to species differences in receptor 
structure and function. Three human a2-adrenoceptor sub- 
type genes, a2-C10, a2-C2 and a2-C4, have been cloned 
[11,14,18] and represent he pharmacologically defined 
receptor subtypes a2n, a21 ~ and C~2c [3]. While the classi- 
cal a2-adrenoceptor radioligand [3H]rauwolscine clearly 
appears to be capable of identifying all three human 
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a2-adrenoceptor subtypes and provides assays to test the 
subtype-selectivity of a2-adrenoceptor ligands [3,9,16], it 
is not ideal for these purposes due to its limited specificity 
towards a2-adrenoceptors and its preferential binding to 
the a2-C4 subtype [16]. Another benzoquinazoline d riva- 
tive, L-657.743 (MK-912), is available in tritiated form 
[ 17], but like [ 3 H]rauwolscine, it is preferentially bound to 
a2-C4-adrenoceptors [16]. Two imidazol(in)e derivatives, 
atipamezole (4-(2-ethyl-2,3-dihydro- 1H inden-2-yl)- 1H- 
imidazole) and RX821002 (2-(2-methoxy-l,4-benzodi- 
oxan-2-yl)-2-imidazoline), have recently been introduced 
as tritiated radioligands for a2-adrenoceptor research 
[12,20] and competition assays using recombinant human 
a2-adrenoceptor subtypes and [3H]rauwolscine have indi- 
cated that these compounds would be relatively subtype- 
nonselective [16]. 
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The characterization f the a2-adrenergic binding of 
[3H]atipamezole has previously been limited to rat tissues 
and human blood platelets, and its usefulness may be 
limited by substantial binding to non-adrenergic sites in 
some tissues [20]. In contrast, studies with [3H]RX821002 
have indicated that it has high specificity for a2-adreno- 
ceptors and that it is a suitable radioligand for the identifi- 
cation of human a2A-type adrenoceptors present on blood 
platelets [5], fat cells [6], in spinal cord homogenates [13], 
and in the human adenocarcinoma cell line HT29 [12]. It 
was recently used to characterize all three cloned human 
c~2-adrenoceptor subtypes expressed in transient COS cell 
cultures [4] and human a2-C10 adrenoceptors in a stably 
transfected CHO cell line [19]. In addition, it has been 
found useful for the characterization f a2-adrenoceptors 
in the rat brain [8,21] and in membranes from neonatal rat 
lung, bovine pineal gland and cultured OK cells [19]. 
Nevertheless, further characterization a d validation was 
needed regarding the use of radioligand binding assays 
with recombinant receptors to screen new potentially sub- 
type-selective a2-adrenoceptor agonists and antagonists. 
The purpose of this study was to carry out such validation 
by determining the kinetics, buffer requirements and per- 
formance in saturation and competition binding assays of 
three structurally different radioligands, [3H]rauwolscine, 
[3H]atipamezole and [3H]RX821002. 
2. Materials and methods 
2.1. Cell culture and preparation of cell homogenates 
Recombinant lines of Shionogi 115 (S 115) mouse mam- 
mary tumour cells expressing the human az-adrenoceptor 
subtypes a2-C10, a2-C2 and a2-C4 [15,16] were cultured 
in roller bottles (1400 cm 2, Nunclon) in DMEM 
(Dulbecco's modified Eagle medium) supplemented with 
20 mM Hepes, 20 mM NaHCO 3, 5% heat-inactivated f tal 
calf serum, 100 U/ml  penicillin, 50 /zg/ml streptomycin, 
1 mM sodium pyruvate and 10 nM testosterone. The cells 
were grown in 5% CO 2 at 37 ° C. Cells were harvested into 
chilled phosphate-buffered saline, pelleted, suspended in 
ice-cold incubation buffer (Tris: 50 mM Tris-HC1, 10 mM 
MgCI 2, 1 mM EDTA (pH 7.4); or K+-phosphate: 50 mM 
(pH 7.4); or glycylglycine: 25 mM (pH 7.4)), and homoge- 
nized with an Ultra-Turrax homogenizer (Model T25, Janke 
and Kunkel, Staufen, Germany; setting 9500 rpm, 2 X 10 
s). Suspensions were stored frozen at - 70 ° C; their stabil- 
ity has been previously demonstrated [16]. Protein concen- 
trations were determined with the method of Bradford [1], 
with bovine serum albumin as the reference standard. 
2.2. Binding assays 
All incubations were performed in triplicate in a 25°C 
water bath with shaking. Receptor binding was measured 
by incubating 100 /zl of cell homogenate (30-50 /zg of 
protein) with [3H]-ligands in a total volume of 250 /zl in 
Tris, K+-phosphate or glycylglycine buffer. After 20 min 
([3H]atipamezole and [3H]RX821002) or 30 min 
([3H]rauwolscine), the incubations were terminated by di- 
lution with 2 ml of ice-cold buffer and rapid filtration 
through glass fibre filters (Whatman GF/B)  using a Bran- 
del M-48R (Gaithersburg, MD, USA) cell harvester in a 
cold room (6 ° C). The filters were washed twice with 5 ml 
of ice-cold buffer, and placed into scintillation vials with 
OptiPhase 'HiSafe' II! (Wallac, Turku, Finland) for count- 
ing at 45% efficiency (Wallac 1410, Wallac). Specific 
binding was defined as the difference between total and 
non-specific binding determined in parallel sets of tubes 
but in the presence of an excess of (-)-adrenaline (100 
~M). 
For kinetic studies of the association reaction, cell 
homogenates were incubated with the [3H]-ligands for 
periods of time ranging from 15 s to 60 min. Rapid 
dilution and filtration were used to terminate the reaction. 
Reversibility of [3H]-ligand binding was assessed by first 
incubating the samples to steady-state and then adding an 
excess of competing drug (100 /~M (-)-adrenaline) to 
displace the bound [3H]-ligand. Specific binding was then 
determined at time points between 1 and 40 min. 
In saturation binding experiments, the final concentra- 
tions of radioligand ranged from 0.03 to 4 nM for 
[3H]atipamezole, from 0.06 to 8 nM for [3H]RX821002 
and from 0.125 to 16 nM for [3H]rauwolscine. 
Competit ion studies were performed using 
[3H]RX821002 concentrations close to its equilibrium dis- 
sociation constant (K d) at each receptor subtype and 13-15 
concentrations of the competitors, oxymetazoline, pra- 
zosin, chlorpromazine, (-)-noradrenaline and UK14,304, 
and (-)-noradrenaline and UK14,304 in the presence of 
the GTP-analogue, Gpp(NH)p (10 /~M). 
2.3. Calculations 
Equilibrium dissociation constants  (Kd) and receptor 
densities (Bma x) were calculated from the results of satura- 
tion experiments u ing computer-assisted data analysis with 
the EBDA-LIGAND package (Elsevier Biosoft, Cam- 
bridge, UK), a non-linear least squares computer program 
(McPherson, 1985). Association and dissociation data were 
analyzed with the KINETIC module of the LIGAND 
program package and inhibition constants (K i) for compet- 
ing drugs were calculated with GraphPAD (GraphPAD 
Software, San Diego, CA). The reported proportions of 
specific binding of total bound radioactivity refer to graph- 
ically estimated values at radioligand concentrations equal 
to the calculated Kd-value of each individual experiment. 
The K d- and Ki-values are presented as geometric 
means _+ S.E. The other results are represented as arith- 
metic means _+ S.E. Student's t-test with two-tailed proba- 
bilities, or one-way analysis of variance (ANOVA) to- 
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gether with the Student-Newman-Keuls-test  were used to 
test the statistical signif icance of  the observed differences 
between group means. 
2.4. Drugs and chemicals 
[3H]Atipamezole (custom synthesized by Amersham, 
Buckinghamshire, UK;  spec. act. 83.9 C i /mmol )  was a 
gift from Orion-Farmos (Turku, Finland). [3H]Rauwols- 
cine (spec. act. 80.5 C i /mmol )  was purchased from 
DuPont -NEN (Dreie ich,  Germany) .  [3H]RX821002 
(specific activity 48 C i /mmol )  was from Amersham. Ati- 
pamezole and UK 14,304 (5-bromo-N-(4,5-dihydro- lH-  
imidazol-2-yl)-6-quinoxal inamine) w re gifts from Orion- 
Farmos. Rauwolscine was from Carl Roth KG (Karlsruhe, 
Germany) and RX821002 was from Research Biochemi-  
cals Inc. (Natick, MA,  USA).  The fol lowing compounds 
were obtained from Sigma (St. Louis, MO, USA):  ( - ) -  
adrenaline, ( - ) -noradrenaf ine ,  oxymetazol ine, prazosin, 
ch lo rpromaz ine  and 5 ' -guany ly l im idod iphosphate  
(Gpp(NH)p). Cell culture reagents were supplied by Gibco 
(Gaithersburg, MD, USA).  ,Other chemicals were of  analyt- 
ical or reagent grade, and were purchased from commer-  
cial suppliers. 
3. Resu l ts  
3.1. Kinetic studies 
Two or three independent association and dissociation 
experiments were performed for each [3H]-l igand with one 
c~2-adrenoceptor subtype, o:2-C 10, in three different buffers 
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Fig. 1. Kinetics of radioligand binding to recombinant human oz2-adreno- 
ceptors. (A) Association and dissociation of [3H]rauwolscine (O), 
[3H]atipamezole ( • ) and [3H]RX821002 (II) in ce2-C10-expressing cell
homogenate in K+-phosphate buffer. (B) Association and dissociation of 
specific [3H]RX821002 binding to three ~2-adrenoceptor subtypes in 
K÷-phosphate buffer: ot2-C10 (11), o~2-C2 (•) ,  ~2-C4 (0). The results 
are representative of 2-3 similar experiments performed in triplicate. 
Table 1 
Comparison of [3H]rauwolscine, [3H]atipamezole and [3H]RX821002 binding to homogenates of Sl15 cells expressing recombinant human o~2-C10- 
adrenoceptors in three different incubation buffers (Tris, K÷-phosphate and glycylglycine) 
Buffer kobs(min- i ) k_l(mi n- i ) K~in(nM) Kd(nM) Bma x n H Specific binding 
(fmol rag- t ) at K d (%) 
[3H]Rauwolscine 
Tris 0.05 + 0.01 (n = 2) 0.02 + 0.01 (n = 2) 2.3 [L] = 3.5 3.1 _ 0.2 (n = 4) 476 5:5 0.99 5:0.01 76 5:5 
K+-phosphate 0.09 + 0.02 (n = 2) 0.03 5- 0.01 (n = 2) 1.5 [L] = 3.0 1.2 5- 0.1 (n = 4) 682 5:32 1.00 5:0.05 82 5:1 
Glycylglycine 0.23 + 0.06 (n = 2) 0.03 ± 0.01 (n = 2) 0.6 [L] = 4.0 0.58 5:0.02 (n = 3) 565 + 42 0.96 5:0.02 91 5:1 
[ 3 H]Atipamezole 
Tris 1.26 _ 0.36 (n = 2) 0.42 + 0.19 (n = 2) 0.45 [L] = 0.9 0.96 5:0.05 (n = 3) 279 5:30 1.01 5:0.01 46 5:4 
K+-phosphate 1.28 5:0.25 (n = 2) 0.26 5:0.09 (n = 2) 0.25 [L] = 1.0 0.47 5- 0.04 (n = 3) 371 5:49 0.97 5:0.03 65 5:3 
Glycylglycine 1.64 + 0.48 (n = 2) 0.13 5:0.01 (n = 2) 0.10 [L] = 1.2 0.26 5:0.05 (n = 4) 201 5:33 0.91 5:0.02 70 5:2 
[3H]RX821002 
Tris 0.26 5:0.04 (n = 2) 0.12 5:0.01 (n = 2) 1.1 [L] = 1.3 0.91 5:0.04 (n = 4) 387 5:34 1.02 -I- 0.03 96 + 1 
K+-phosphate 0.39 5: 0.20(n=3) 0.094 5: 0.004(n=2) 0.48[L]= 1.5 0.48 5- 0.07(n=4) 478_+52 1.00+0.03 96+1 
Glycylglycine 0.51 5: 0.18(n=2) 0.115:0.02(n=2) 0.33[L]= 1.2 0.26 5-0.01(n=4) 386+23 0.94 5:0.03 98+ 1 
Data from kinetic and saturation experiments. Specificity of binding was defined with (-)-adrenaline (100 ~M). Association rate constants (kobs), 
dissociation rate constants (k j), kinetically derived equilibrium dissociation constants (Kk in ;  K kin = k Jk+ t), equilibrium dissociation constants (Kd), 
receptor densities (Bmax), Hill coefficients (n H) and proportions of specific binding were calculated. The calculated kinetic constants of the association 
reaction (k+ 1 ) were derived from the equation k+ i = (kobs-k-I)/[L], where [L] is the free radioligand concentration ( M). Results are means 5: S.E from 
2-4 separate xperiments performed in triplicate. 
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(Tris, K+-phosphate and glycylglycine). Fig. IA shows 
representative r sults obtained in K+-phosphate buffer. 
The association reactions of all three [3H]-ligands were 
rapid, and steady-state was reached within 20 min for 
[3H]atipamezole and [3H]RX821002 and within 30 min for 
[3H]rauwolscine in all three buffers at 25°C. Computer 
analysis indicated that association was a single-exponential 
process; the calculated rate constants (kob ~) are shown in 
Table 1. When 100 /xM (-)adrenaline was added to 
receptor preparations at steady-state with the [3H]-ligands, 
the resulting dissociation also followed a monoexponentiai 
course. The calculated issociation rate constants (k_~) are 
shown in Table 1. Kinetic equilibrium dissociation con- 
stants (K~") were derived from these results. These values 
were in good agreement with the equilibrium dissociation 
constants (K d) calculated from saturation binding experi- 
ments, as shown in Table 1. Similar kinetic experiments 
were also performed with [3H]RX821002 in K+-phosphate 
buffer for the other two a2-adrenoceptor subtypes, a2-C2 
(kob~: 0.57 + 0.13 min-l; n = 2, k_ i: 0.23 + 0.05 min-1; 
n = 2, "~d/d'kin = 1.83 nM; [L] = 2.7 nM) and c~2-C4 (kobs: 
0.75 + 0.25 min-~ ; n = 2, k_ l: 0.25 _ 0.01 min- i ; n = 2, 
Kkin = 0.60 nM; [L] = 1.2 nM) (Fig. 1B). d 
3.2. Saturation binding 
Equilibrium dissociation constants (K d) and receptor 
density values (Bma x) for the oz2-C10 receptor were deter- 
mined with [3H]rauwolscine, [3H]atipamezole and 
[3H]RX821002 in the three buffer systems. Aliquots of a 
single batch of cell homogenate were used in all experi- 
ments. These results are shown in Table 1. Fig. 2 illus- 
trates the saturation binding results of [3H]rauwolscine, 
[3H]atipamezole and [3H]RX821002 in K+-phosphate. The 
receptor affinities were highest in glycylglycine, almost 
equally high in K+-phosphate, and lowest in Tris buffer for 
all three [3H]-ligands (ANOVA: P < 0.01). The apparent 
(-)-adrenaline-defined r ceptor densities (Bma x) tended to 
be highest in K+-phosphate (ANOVA: P<0.05  for 
[3H]rauwolscine and [3H]atipamezole, not significant for 
[3H]RX821002). Hill coefficients (n H) were not different 
from unity. At radioligand concentrations equal to the 
calculated K d values, non-specific binding represented 
only 2-4% of total binding of [3H]RX821002, whereas 
non-specific binding was higher with [3H]rauwolscine (9- 
24%) and [3H]atipamezole (30-54%). Consequently 
[3H]RX821002 was chosen for further studies. Equilibrium 
dissociation constants (K d) for [3H]RX821002 in K +- 
phosphate buffer were 0.48 + 0.07 nM (Bma x= 478 _+ 52 
fmol mg-l ;  n = 4) for o/2-C10, 3.07 ___ 0.27 nM (Bma x = 
2500 _ 248 fmol mg-~; n = 2) for c~2-C2 and 0.63 ___ 0.13 
nM (Bmax = 1468+343 fmol mg-l ;  n=3)  for a2-C4. 
All K d values were slightly (20-30%) but not statistically 
significantly higher in K+-phosphate buffer supplemented 
with 10 mM MgC12. 
Non-specific binding (defined with 100/xM (-)-adren- 
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Fig. 2. Saturation isotherms of [3H]ranwolscine (A), [3H]atipamezole (B), 
and [3H]RX821002 (G) binding in a homogenate of transfected S] 15-or 2- 
CI0 cells. The preparations were incubated in K+-phosphate buffer at 
25 ° C for 30 min ([3H]rauwolscine) or for 20 min ([3H]atipamezole and 
[3H]RX821002). The results are representative of 3-4 similar experi- 
ments, each performed in triplicate. Symbols: total binding (z~), non- 
specific binding in the presence of 100 tzM (-)-adrenaline (rq), and 
specific binding (total-non-specific) (0) .  
aline) of [3H]RX821002 and [3H]rauwolscine to ho- 
mogenates of S 115 cells expressing human az-C 10-adren- 
oceptors was a linear function of the free radioligand 
concentration (Fig. 2A,C). No specific binding was de- 
tected with these radioligands in non-transfected Sl15 
cells, irrespective of whether (-)-adrenaline (100 /zM), 
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Table 2 
Inhibition of [3H]RX821002 binding to recombinant a2-adrenoceptor subtypes by oxymetazoline, prazosin, chlorpromazine, (-)-noradrenaline and 
UK14,304 in the absence and presence of 10/.~M Gpp(NH)p in K+-phosphate buffer 
Drug ot2-C 10 ot2-C2 ot2C4 
K i (nM) n n K i (nM) n n K i (nM) n H 
Oxymetazoline 1.98 + 0.49 (n = 2) 0.77 5:0.08 1406 + 219 (n = 3) 0.87 + 0.05 51.6 5:5.1 (n = 2) 1.08 5:0.18 
Prazosin 769_+ 15 (n= 2) 1.075:0.08 67.3 + 0.1 (n = 2) 1.165:0.01 19.1 5:2.1 (n = 2) 1.095-0.10 
Chlorpromazine 1008 + 178 (n = 2) 1.08 + 0.07 33.5 5:5.8 (n = 3) 1.06 _ 0.06 85.3 5:1.7 (n = 2) 1.30 + 0.02 
( - )-Noradrenaline 43.6 + 9.0 (n = 5) 0.535:0.04 284 + 27 (n = 2) 0.735:0.03 84.5 5:15.0 (n = 7) 0.685-0.04 
(-)-Noradrenaline + Gpp(NH)p 296 5:49 (n = 4) 0.61 + 0.05 314 + 6 (n = 2) 0.82 5:0.01 119 + 24 (n = 7) 0.83 5:0.05 
UK14,304 3.24 + 0.65 (n = 4) 0.49 + 0.02 444 5:5 (n = 2) 0.81 5- 0.07 249 + 102 (n = 6) 0.56 5:0.04 
UK + Gpp(NH)p 14.5 + 3.7 (n = 4) 0.63 + 0.07 450 5:32 (n = 2) 0.95 + 0.02 289 5- 13 (n = 6) 0.77 5:0.03 
Apparent inhibition constants (K i) and Hill coefficients (n H) were obtained from computer analysis of binding data. Values are means + S.E. from 2-7 
separate xperiments performed in triplicate. 
unlabeUed RX821002 or unlabelled rauwolscine (10 /zM) 
was used to define specificity of binding. The non-specific 
background binding of these ligands was entirely caused 
by binding to the filter paper, i.e., similar counts were 
obtained also when cell homogenate was omitted from the 
incubations. Binding to filter paper was 0.25 _ 0.02% of 
total added radioactivity for [3H]rauwolscine and 0.18 + 
0.01% for [3H]RX821002. In contrast, the ( - ) -  
adrenaline-defined non-specific binding of [3H]atipame- 
zole was composed of two populations of sites, one sat- 
urable and the other non-saturable and linearly related to 
free radioligand concentration (Fig. 2B). Also in non-trans- 
fected S115 cells, [3H]atipamezole identified a (-)-adren- 
aline-insensitive, non-adrenergic saturable binding site. Us- 
ing unlabelled atipamezole (10 /zM) to define specificity 
of binding, this site was preliminarily characterized as 
having a Ka of 1.1 ___ 0.3 nM and a Bma x of 76 _ 24 fmol 
mg-f protein in K+-phosphate buffer (20 min incubation, 
n = 4). [3H]Atipamezole binding to filter paper epresented 
0.53 +__ 0.04% of total added radioactivity. 
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Fig. 3. Linear regression analysis of K i values for inhibition of 
[3H]RX821002 (in K + phosphate:) and [3H]rauwolscine (in Tris buffer) 
binding to recombinant human or2-adrenoceptor subtypes by three com- 
peting drugs. 1 = oxymetazoline, a2-C10; 2 = prazosin, ot2-Cl0; 3 = 
chlorpromazine, a2-C10; 4 = oxymetazoline, ot2-C2; 5 = prazosin, ct 2- 
C2; 6 = chlorpromazine, a2-C2; 7 = oxymetazoline, ct2-C4; 8 = prazosin, 
ot2-C4; 9 = chlorpromazine, ot2-C4. Pearson correlation coefficient r = 
0.94. Dashed line: line of identity; solid line: actual regression equation 
(log y=0.918(log x)-0.121).  
3.3. Inhibition of [3H]RX821002 binding 
Binding of [3H]RX821002 to human az-adrenoceptor 
subtypes a2-Cl0, a2-C2 and a2-C4 (1 nM for a2-C10 
and a2-C4 and 3 nM for a2-C2) was inhibited in a 
concentration-dependent ma ner by co-incubation with five 
competing agents, (-)-noradrenaline, UK14,304, 
oxymetazoline, prazosin and chlorpromazine. The agonists 
(-)-noradrenaline and UK14,304 were also tested in the 
presence of the GTP-analogue Gpp(NH)p (10 /xM) (Table 
2). The rank order of affinity of three previously identified 
az-adrenoceptor subtype selective drugs was a2-C10 > 
a2-C4 > a2-C2 for oxymetazoline, a2-C4 > a2-C2 > a z- 
C10 for prazosin and a2-C2 > a2-C4 > a2-C10 for chlor- 
promazine. Similar results were previously obtained with 
[3H]rauwolscine in Tris buffer [16]; the K i values deter- 
mined in these two systems were in close agreement 
(r--0.94) (Fig. 3). The tendency to biphasic competition 
by the agonists (-)-noradrenaline and UK14,304 for 
[3H]RX821002 binding (in K+-phosphate + 10 mM 
MgCI 2) was abolished in the presence of 10/xM Gpp(NH)p 
(Fig. 4). The displacement curves were shifted signifi- 
cantly to the right, and their slopes were clearly steeper 
compared to experiments with (-)-noradrenaline and 
UK14,304 in the absence of Gpp(NH)p. The extent of the 
Gpp(NH)p-induced shift was largest in the a2-C10 sub- 
type, smaller in the a2-C4 subtype, and minimal in the 
a2-C2 subtype (Fig. 4.; see Table 2 for Hill coefficients). 
Higher protein concentrations (80-100 /zg/tube) were 
used in these experiments in order to minimize assay 
variation. 
4. Discussion 
The purpose of this study was to evaluate the usefulness 
of [3H]rauwolscine, [3H]atipamezole and [3H]RX821002 
as radioligands for the characterization f human a 2- 
adrenoceptor subtypes in recombinant Sl15 cells. Opti- 
mized and validated radioligand binding assays are needed, 
e.g., when recombinant receptors are used to screen new 
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potentially subtype-selective c~2-adrenoceptor agonists and 
antagonists. [3H]RX821002 had clearly lower non-specific 
binding and somewhat higher receptor affinity than 
[3H]rauwolscine in this assay system. [3H]RX821002 thus 
has distinct advantages compared to the classical a 2- 
adrenoceptor radioligand [3H]rauwolscine, and as it also 
fulfils other equirements placed by receptor binding assay 
technology [2], it emerges as a very useful tool for the 
characterization f all three human a2-adrenoceptor sub- 
types. 
An optimal radioligand for characterization of a 2- 
adrenoceptor subtypes and screening of a2-adrenoceptor 
subtype-selective agents hould be highly specific for of 2- 
adrenoceptors. At the same time, it should be subtype-non- 
selective, i.e., it should have equal, high affinity for all 
three c~2-adrenoceptor subtypes. Both [3H]rauwolscine and 
[3H]RX821002 clearly fulfil the former requirement in 
Sl15 cells, but neither is entirely subtype-nonselective. 
[3H]Rauwolscine is known to have an affinity rank order 
of c%-C4 > ce2-C2 = ce2-C10 [3,16], although its affinity 
differences between the human ce2-adrenoceptor subtypes 
(five-fold range) are clearly smaller than those between 
their rodent homologues [7]. As in our previous study 
where unlabelled RX821002 was used to compete for 
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[3H]rauwolscine binding [16], [3H]RX821002 was ob- 
served to have an affinity rank order of a2-Cl0 > %-C4 
> %-C2. Whereas we expected only a two-fold affinity 
difference between a2-C10 and a2-C2 [16], the difference 
between the K d of [3H]RX821002 to a2-Cl0 and c~2-C2 
receptors turned out to be approximately 6-fold, i.e., simi- 
lar to that of [3H]rauwolscine. Similar affinity differences 
for [3H]RX821002 binding; between the a2-adrenoceptor 
subtypes were recently also reported by others [4,19]. 
In contrast o the high c~:-adrenoceptor specificity of 
[3H]rauwolscine and [3H]RX821002, [3H]atipamezole also 
identified a non-adrenergic saturable population of binding 
sites in homogenates of S 115 cells. Unlabelled atipamezole 
was used to define this binding, but subsequent experi- 
ments have indicated that also other imidazoles are capable 
of binding to this site (B. SjiSholm, unpublished). 
[3H]Atipamezole has previously been shown to bind to 
both ct2-adrenoceptors and non-adrenergic imidazole sites 
in rat tissues [20], and is thus not generally applicable as 
an az-adrenoceptor radioligand. [3H]Atipamezole may, 
however, be a useful agent for the characterization f
non-adrenergic imidazole binding sites, and experiments o
elucidate the properties of such sites on non-transfected 
Sl15 cells are in progress. 
Kinetic characterization is essential in the validation of 
a receptor binding assay. Recombinant cell lines express- 
ing different ct2-adrenoceptor subtypes are very useful for 
such validation, since the receptors are available as un- 
mixed populations, unlike they are in tissues, and they can 
be studied in identical physical, chemical and biological 
environments. Kinetic experiments showed that binding of 
all three tested [3H]-ligands to c~2-C10-adrenoceptors in 
three different buffers and of [3H]RX821002 to all three 
human a2-adrenoceptor subtypes in K+-phosphate buffer 
was rapid and reversible. Both association and dissociation 
were accurately described as monoexponential processes, 
which is consistent with a simple bimolecular model of the 
receptor-ligand interactions [2,10]. The also previously 
reported higher c~2-adrenoceptor affinities in glycylglycine 
and K+-phosphate buffer compared to Tris-HCl [3] were 
found to be due to faster rates of association in these 
buffers. The affinities of [3H]rauwolscine, [3H]atipamezole 
and [3H]RX821002 to human a2-C10 were similarly influ- 
enced by assay buffer composition. Binding capacity of 
a:-C10 receptors was higher for all three radioligands in 
K+-phosphate buffer than in Tris or glycylglycine. No 
obvious mechanistic explanation can be given for this 
observation. 
Association and dissociation rates of [3H]RX821002 in 
K+-phosphate buffer at 25°C were somewhat slower in 
a2-C10 than in the other two receptor subtypes. Neverthe- 
less, [3H]RX821002 binding reached steady-state at all 
three c~:-adrenoceptor subtypes in 15 min, and the presently 
employed assay procedure with a 20 min incubation time 
is thus suitable for assays of all three human receptor 
subtypes. Dissociation was sufficiently slow to allow effi- 
cient separation of bound and free radioactivity by conven- 
tional filtration methods [2]. The use of reduced tempera- 
tures during the separation phase further improves the 
accuracy of saturation binding experiments. Kinetic equi- 
librium dissociation constants and those derived from re- 
gression analysis of saturation experiments were in close 
agreement, confirming the validity of the saturation assays. 
Oxymetazoline, prazosin and chlorpromazine have pre- 
viously been reported as compounds capable of discrimi- 
nating between the human a2-adrenoceptor subtypes in 
binding assays employing [3H]rauwolscine [3,16]. The 
similar results obtained with [3H]RX821002 in Tris-Mg 2+ 
buffer [4] and now in K+-phosphate buffer further support 
the validity of the use of [3H]RX821002 in screening 
assays for a2-adrenoceptor subtype-selective agents. Our 
results expand this notion to include az-adrenoceptor ago- 
nists, as well (in K+-phosphate buffer supplemented with 
10 mM MgC12), since UK 14,304 was found to be signifi- 
cantly more potent in competition with [3H]RX821002 
binding at a2-C10 compared to a2-C4 and a2-C2 recep- 
tors (130- and 90-fold differences in Ki). Similar prefer- 
ential binding of UK 14,304 to a2-C10 has previously 
been observed in competition assays with [3H]rauwolscine 
in Tris-Mg 2+ buffer [9]. Also (-)-noradrenaline had 
somewhat higher affinity to c~2-C10 than to the other two 
receptor subtypes (in assays without Gpp(NH)p); previous 
results with [3H]rauwolscine were similar [9]. 
All three human a2-adrenoceptor subtypes are coupled 
to inhibition of adenylyl cyclase activity through pertussis 
toxin-sensitive G-proteins in recombinant Sl15 cells [9]. 
While competition binding assays are a convenient method 
to assess the subtype-selectivity of az-adrenoceptor antag- 
onists [16], such assays alone are insufficient for the 
characterization f agonists. Nevertheless, careful use of 
binding assays combined with appropriate functional as- 
says to validate the results may provide valuable informa- 
tion on agonist-receptor interactions. It is believed that the 
high-affinity component of agonist binding to c~2-adreno- 
ceptors reflects a receptor state based on a 'ternary com- 
plex' between agonist, receptor and a guanine nucleotide- 
binding G-protein [10]. GTP-analogues destabilize this 
complex, conferring the receptors to a low-affinity state. In 
line with this, the competition binding curves of the ago- 
nists UK 14,304 and (-)-noradrenaline were shifted sig- 
nificantly to the right in the presence of the stable GTP- 
analogue Gpp(NH)p (10 /zM). The extent of the GTP-in- 
duced shift was largest in c~2-C10, intermediate in c~2-C4 
and minimal in the a2-C2 subtype. Identical agonist bind- 
ing results were previously obtained with [3 H]rauwolscine 
as radioligand in Tris-Mg 2+ buffer [9]. The reasons for the 
differential GTP-sensitivity of the receptor subtypes are 
not clear, but different receptor densities do not explain the 
phenomenon; maybe it is related to different coupling 
efficiency of the ot2-adrenoceptor subtypes in Sl15 cells 
[9]. 
In conclusion, our results from kinetic, saturation and 
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competition binding assays upport he validity of the use 
of [3H]RX821002 as radioligand for the characterization f 
all three human c~z-adrenoceptor subtypes in transfected 
cells. This assay system appears to be well suited for the 
determination f the subtype-selectivity of new a2-adren- 
oceptor agonists and antagonists. 
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